Redhill Biopharma (XTAE:RDHL) ROCE % : 124.65% (As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Redhill Biopharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Redhill Biopharma's annualized ROCE % for the quarter that ended in Jun. 2023 was 124.65%.

Redhill Biopharma ROCE % Historical Data

The historical data trend for Redhill Biopharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma ROCE % Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-72.57

-74.75

-78.54

-99.24

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-	-	-	124.65	-

Redhill Biopharma ROCE % Calculation

Redhill Biopharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	90.683	/	( ( (592.41 - 736.286)	+	(85.94 - 71.751) )	/ 2 )
	=	90.683	/	( (-143.876	+	14.189)	/ 2 )
	=	90.683	/	-64.8435
	=	-139.85 %

Redhill Biopharma's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	40.08	/	( ( (219.386 - 180.62)	+	(130.649 - 105.106) )	/ 2 )
	=	40.08	/	( ( 38.766	+	25.543 )	/ 2 )
	=	40.08	/	32.1545
	=	124.65 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Redhill Biopharma (XTAE:RDHL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Redhill Biopharma ROCE % Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (XTAE:RDHL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (XTAE:RDHL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RDHL:USA 2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.